HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Postoperative progression of pulmonary metastasis in osteosarcoma.

Abstract
Early relapse with distant metastasis often is observed in patients with cancer after resection of the primary tumor. It is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis. The authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models. Matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal (tumor intact group, 1.61 +/- 0.21 g/dL; tumor removed group, 4.92 +/- 0.35 g/dL). In addition, serum concentration of the angiogenesis inhibitor, endostatin, decreased significantly after primary tumor removal. Treatment with the antiangiogenic reagent TNP-470 suppressed postoperative progression of pulmonary metastasis. These results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis. The current data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively.
AuthorsTakeo Tsunemi, Satoshi Nagoya, Mitsunori Kaya, Satoshi Kawaguchi, Takuro Wada, Toshihiko Yamashita, Seiichi Ishii
JournalClinical orthopaedics and related research (Clin Orthop Relat Res) Issue 407 Pg. 159-66 (Feb 2003) ISSN: 0009-921X [Print] United States
PMID12567143 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Cyclohexanes
  • Endostatins
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Peptide Fragments
  • Sesquiterpenes
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Collagen
  • O-(Chloroacetylcarbamoyl)fumagillol
Topics
  • Angiogenesis Inhibitors (blood, therapeutic use)
  • Animals
  • Bone Neoplasms (pathology, prevention & control, surgery)
  • Collagen (blood)
  • Cyclohexanes
  • Disease Models, Animal
  • Endostatins
  • Endothelial Growth Factors (blood)
  • Female
  • Intercellular Signaling Peptides and Proteins (blood)
  • Lung Neoplasms (blood, prevention & control, secondary)
  • Lymphokines (blood)
  • Mice
  • Mice, Inbred BALB C
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Osteosarcoma (prevention & control, secondary, surgery)
  • Peptide Fragments (blood)
  • Postoperative Complications
  • Sesquiterpenes (blood, therapeutic use)
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: